BioInvent International AB (publ) (BOVNF)価格

BioInvent International AB is a clinical-stage biotech company that discovers and develops novel and immuno-modulatory antibodies for cancer therapy. The company is headquartered in Lund, Skane and currently employs 124 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.